Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.

PubWeight™: 1.16‹?› | Rank: Top 10%

🔗 View Article (PMID 25409469)

Published in Clin Infect Dis on November 18, 2014

Authors

Sharon M Seifert1, David V Glidden2, Amie L Meditz3, Jose R Castillo-Mancilla4, Edward M Gardner5, Julie A Predhomme1, Caitlin Rower1, Brandon Klein1, Becky J Kerr1, L Anthony Guida1, Jia-Hua Zheng1, Lane R Bushman1, Peter L Anderson1

Author Affiliations

1: Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora.
2: Department of Epidemiology and Biostatistics, University of California, San Francisco.
3: Beacon Center for Infectious Disease, Boulder Community Hospital.
4: School of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora.
5: School of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora Denver Public Health, Colorado.

Associated clinical trials:

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status | NCT01040091

Articles citing this

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis (2016) 1.26

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses (2015) 1.08

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. Antimicrob Agents Chemother (2015) 0.85

Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Res Hum Retroviruses (2016) 0.83

Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM). AIDS Behav (2016) 0.82

Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrob Agents Chemother (2016) 0.82

Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother (2016) 0.77

Pharmacology supports on-demand PrEP. Lancet HIV (2016) 0.77

Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS (2016) 0.76

When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Cult Health Sex (2016) 0.76

Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells. Antimicrob Agents Chemother (2015) 0.75

Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. Antimicrob Agents Chemother (2015) 0.75

Levels of intracellular phosphorylated tenofovir and emtricitabine correlate with natural substrate concentrations in peripheral blood mononuclear cells of persons prescribed daily oral TruvadaTM for HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2017) 0.75

Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. J Int AIDS Soc (2017) 0.75

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad (2017) 0.75

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46

Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity (2007) 6.36

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis (2014) 5.59

Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85

Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol (1998) 3.16

Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep (2012) 2.95

Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41

Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal (2011) 2.10

Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep (2013) 1.72

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One (2012) 1.12

Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. AIDS Behav (2015) 1.03